Rewards for Evidence of Ambulance Fraud Available to Whistleblowers Under the False Claims Act, According to Young Law Group

Philadelphia, PA (PRWEB) April 28, 2014

The fraudulent billing of Medicare by ambulance companies is an area prime for whistleblowers with the U.S. Department of Health and Human Services estimating that ambulance providers were overpaid more than $ 300 million last year.* Employees who identify that their company is charging Medicare illegally may earn a substantial reward if they report their evidence through the procedures set up by the False Claims Act and the United States recovers money from the company as a result.

Medicare pays for transportation by ambulance when it is medically necessary. “Although there are dialysis and cancer patients who may appropriately require rides for treatment, unscrupulous service providers will offer ambulance rides to patients who they could safely transport in a wheelchair van or could drive their own vehicle. The owners implement this practice in order to line their pockets because the government will reimburse more for ambulance transportation,” commented Eric L. Young, Esq., Managing Partner of Young Law Group.

Other practices which may violate the False Claims Act include the billing for emergency services in non-emergency situations, business acquired by referral agreements prohibited under the Anti-Kickback Statute and under the table payments to patients are also prohibited.

“Employees at companies engaged in this misconduct should consult with an attorney to determine their rights,” said Young. The Young Law Group offers a free, confidential evaluation to potential whistleblowers who have evidence of fraud by ambulance providers against the U.S. government. Please call 1-800-590-4116 for additional information.

“The federal government revised the False Claims Act in 1986 to strengthen the public-private partnership in the fight against fraud,” declared James J. McEldrew, III, Esq., Of Counsel to Young Law Group. “The government can not investigate every bill submitted by Medicare service providers in order to determine whether the charge is valid. It relies, in part, on ethical individuals working for the companies and others who come across evidence of fraud to report it.”

The False Claims Act authorizes individuals to report fraudulent bills submitted to and paid by Medicare in a qui tam lawsuit. If the government or the relator, as the whistleblower filing the lawsuit is commonly known, is able to recover money paid out by the government through litigation, the relator may receive between 15 and 30 percent of the amount recovered. The law also provides whistleblowers with protection against retaliation by authorizing a federal lawsuit for damages when an employer changes the terms and conditions of their employment due to lawful whistleblowing.

Earlier this month, the payment data for $ 77 billion paid through Medicare Part B to 880,000 providers in 2012 was released by the Centers for Medicare and Medicaid Services (CMS).** The $ 5 billion paid by Medicare to ambulance companies in 2012 was more than was paid to orthopedic surgeons or cancer doctors.*

The Medicare data reveals that the program pays fifty percent more per patient, on average, to providers in West Virginia, Massachusetts, South Carolina and New Jersey for transportation. This may signal fraudulent billing but insiders are needed to confirm it with actual evidence of fraud. The U.S. government has already identified Houston, Texas and Philadelphia, Pennsylvania as areas where illegal billing is likely to originate. New ambulance companies are not permitted to register with Medicare and Medicaid in these two regions at present.

About Young Law Group, P.C.

Young Law Group represents whistleblowers reporting health care fraud to the U.S. Government via qui tam lawsuits permitted by the False Claims Act. Young Law Group also represents individuals reporting securities fraud to the SEC/CFTC programs and tax evasion to the IRS.

Eric L. Young, Esq., Managing Partner of Young Law Group, represented the first whistleblower awarded compensation by the IRS under the mandatory reward program created following the Tax Relief and Health Care Act of 2006. Young has also served as an expert witness in areas of U.S. whistleblower law and represented clients in some of the largest qui tam recoveries, including United States ex. rel. Lucia Paccione v. Cephalon Inc., E.D.P.A., 03-CV-6268.

For a free, confidential case evaluation and discussion about whistleblower laws and rights, please call Eric Young, Esq., at 1-800-590-4116.

Young Law Group, P.C., is a private law office located at 123 S. Broad St., Ste 1920, Philadelphia, PA 19109 with attorneys licensed to practice in Pennsylvania. The firm will associate with local counsel in other jurisdictions when necessary. Young Law Group may not be able to represent residents of all states.

Learn more about Eric Young, Esq., and Young Law Group at

For attribution purposes:


Digital Evidence & Forensics Boot CD Disc Disk DVD [PC-LINUX-MAC-MOBILE]

Digital Evidence & Forensics Boot CD Disc Disk DVD [PC-LINUX-MAC-MOBILE]

Digital Evidence & Forensics Boot CD Disc Disk DVD [PC-LINUX-MAC-MOBILE]

  • Digital Evidence & Forensics Boot Disc is a distribution made for Computer Forensics, with the purpose of running live on systems without tampering or corrupting devices such as hard disks, pendrives, etc…, that are connected to the system where the boot process takes place.
  • Use this disc to extract information or access the devices connected to it such as phones, flash drives, usb and other connection types.
  • Ideal for Military, Government Officers, Law Enforcement Investigators, Expert Witnesses, IT Auditors, Universities, & learning for Individuals

Azere Digital PC Forensics and Cyber Inteligence
Digital Evidence & Forensics Boot Disc is made for Computer Forensics, with the purpose of running live on systems without tampering or corrupting devices such as hard disks, pendrives, etc…, that are connected to the system where the boot process takes place.
Use this disc to extract information or access the devices connected to it such as phones, flash drives, usb and other connection types.
Complete set of utilities for a wide range of IT

List Price: $ 122.49


Find More Expert Witness Products

Zoloft, SSRI Birth Defect Allegation Lawsuits: Resource4thePeople Awaits Key Evidence Ruling

San Diego, CA (PRWEB) April 22, 2014

Resource4thePeople announced today that a key ruling is being awaited in litigation* alleging that birth defects have been caused by the use of Zoloft and other antidepressants known as selective serotonin reuptake inhibitors (SSRIs).

Lawyers for hundreds of families who are seeking compensation over these allegations and attorneys for the manufacturers of the medications have recently been presenting arguments to the judge overseeing the cases over which expert testimony will be allowed at trials.

“These hearings are very important because both sides want to present the most qualified experts in the field of birth defects and medications in the upcoming trials over these SSRI birth defect allegations,” said Resource4thePeople.

“As we await the judge’s ruling we remain committed to updating consumers about this litigation and continuing our policy of free consultations about legal options to seek compensation over these allegations.

Hundreds of such federal lawsuits from across the country have been grouped together* alleging women who used SSRIs such as Zoloft before or during their pregnancies gave birth to infants suffering serious health defects.

The cases are under the jurisdiction of District Judge Cynthia Rufe, who has scheduled the first bellwether trial from this pool of Zoloft lawsuits for Nov. 3, 2014, according to the court file.

“The first bellwether trial is several months away but there is still time for consumers who may have been affected by the allegations against Zoloft and other SSRIs to file their own claims,” said Resource4thePeople.

In the meantime, Resource4thePeople has updated its web site to provide consumers with more information about allegations involving SSRIs and birth defects.

“This site includes valuable information for consumers who may have been affected by allegations that the use of an SSRI before or during pregnancies caused a birth defect in an infant,” said Resource4thePeople.

“Among the most important details provided is information about how to obtain a free consultation to determine whether there is eligibility to seek compensation for medical expenses, treatment, training and other expenses involved in overcoming a birth defect.”

The site also includes detailed descriptions of SSRIs, U.S. Food and Drug Administration health warnings, medical research findings, descriptions of birth defects and an outline of what is contained in an SSRI allegations lawsuit.

The information may be accessed at:

SSRI anti-depressants are sold under various brand and generic drug names such as Zoloft, Prozac, Paxil, Lexapro, Celexa and Depakote and are described by The National Institute of Mental Health as the most popular antidepressants prescribed in the United States.**

In another development, statistics*** compiled by federal court officials show that there were 475 Zoloft lawsuits under Judge Rufe’s supervision in the U.S. District Court for the Eastern District of Pennsylvania.

The SSRI lawsuits assigned to Judge Rufe include allegations of at least one life-threatening birth defect. Here is a detailed list of some of the defects that have been identified in these federal lawsuits:

— Persistent pulmonary hypertension of the newborn, also identified as PPHN. This is perhaps the most serious of the defects because it affects the lungs and heart and has about a 10 percent fatality rate.

    — Clubfoot, or deformed feet. This is a condition in which an infant’s feet twist inward or face downward.

    — Atrial septal or ventrical septal defects in which infants are born with holes in their hearts.

    — Craniosynostosis, which is a cranial deformity in the fetus which can cause serious problems, including seizures after birth.

    — Omphalocele, which is a condition in which an infant’s internal organs may form outside of the body.

— Other birth defects, including Tetralogy of Fallot, spina bifida, transposition of the arteries and heart murmurs.

“If any family has a child who suffers from any of these conditions we urge them to contact our national network of attorneys as soon as possible for a consultation about their rights to seek compensation for health issues that may have been caused by the use of these antidepressants before or during a pregnancy,” said Resource4thePeople.

Judge Rufe has selected 25 cases from the consolidated lawsuits to serve as bellwether trials in which lawyers for the plaintiffs and those for the defense can test the strengths and weaknesses of their cases, according to the court file.

Judge Rufe is also overseeing a parallel multidistrict litigation**** involving claims that another antidepressant known as an SNRI, Effexor, also may cause birth defects in infants born to women who took the medication shortly before or during pregnancies.

Federal court figures show that there are now 52 Effexor cases before Judge Rufe.

One of the most recent warnings questioning the effectiveness and addressing side effects involving SSRIs was published Aug. 19, 2013 in The New York Times***** in an article by a physician who laments the lack of progress in developing effective, safe antidepressants.

“This is just the latest of the concerns raised about the effectiveness and safety of SSRIs,” said Resource4thePeople.

“As the physician points out, whether or not these medications such as Zoloft, Paxil, Prozac and Lexapro are providing safe, effective treatment for depression is open to debate.”

Persistent pulmonary hypertension of the newborn is among several birth defect issues linked to SSRIs raised by the U.S. Food and Drug Administration in a 2006 Public Health Advisory.******


*In Re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation – MDL 2342, United States District Court for the Eastern District of Pennsylvania

**NIMH, 2008;


**** MDL – 2458 IN RE: Effexor (Venlafaxine Hydrochloride) Products Liability Litigation


******FDA, December 14, 2011;

Find More Expert Witness Press Releases